




GRAND ROUNDS Joseph J. Decker, MD Cardiac Electrophysiology Minneapolis Heart Institute





2



































ate vs Rhythm Control	TABLE 3. Adverse Events.*						
The New England Journal of Medicine		Event	Overall (N=4060)	RATE-CONTROL GROUP (N=2027)	RHYTHM-CONTROL GROUP (N=2033)	P VALUE	
Copyright © 2100 3 by the Manachastern Minfald Record VOLUME 347 DUCEMERS 5, 2002 NUMBER 23				no. of patients (%)		
Ø		Primary end point (death)	666 (26.3)	310 (25.9)	356 (26.7)	0.08†	
A COMPARISON OF RATE CONTROL AND RHYTHM CONTROL IN PATIENTS WITH ATELLA I BRILLATION		Secondary end point (composite of death, disabling stroke, disabling anoxic encephalopathy, major bleeding, and cardiac arrest)	861 (32.3)	416 (32.7)	445 (32.0)	0.33	
THE ATRIAL FURNILATION FOLLOW-UP INVESTIGATION OF FLOTTINE MANAGEMENT (AFFIRM) INVESTIGATIONS*	*	Torsade de pointes	14 (0.5)	2 (0.2)‡	12 (0.8)	0.007	
Dendemized multicenter comparison		Sustained ventricular tachycardia	15 (0.6)	9 (0.7)	6 (0.6)	0.44	
Randomized, multicenter comparison rate vs rhythm control		Cardiac arrest followed by resuscitation Ventricular fibrillation or ventricular tachycardia Pulseless electrical activity, bradycardia, or other rhythm	19 (0.6) 10 (0.3)	10 (0.7) 1 (<0.1)	9 (0.5) 9 (0.6)	0.83 0.01	
N=4060		Central nervous system event					
Mortality at five years		Total Ischemic stroke§	211 (8.2) 157 (6.3)	105 (7.4) 77 (5.5)	106 (8.9) 80 (7.1)	0.93	
Rhythm control 24%		After discontinuation of warfarin	69	25	44	0.0 0	
 Rate control and 21% 		During warfarin but with INR <2.0 Concurrent atrial fibrillation	44 67	27 42	17 25		
Rate control and 21%		Primary intracerebral hemorrhage	34 (1.2)	18 (1.1)	16 (1.3)	0.73	
2 ³⁰] P=0.08		Subdural or subarachnoid hemorrhage Disabling anoxic encephalopathy	24 (0.8) 9 (0.3)	11 (0.8) 4 (0.2)	13 (0.8) 5 (0.4)	0.68 0.74	
€ 25- -		Myocardial infarction	9 (0.3)	4 (0.2) 67 (4.9)	5 (0.4) 73 (6.1)	0.60	
Rhythm control		Hemorrhage not involving the central nervous system	203 (7.3)	107 (7.7)	96 (6.9)	0.44	
Rhythm control		Systemic embolism	16 (0.5)	9 (0.5)	7 (0.4)	0.62	
2		Pulmonary embolism	8 (0.3)	2 (0.1)	6 (0.5)	0.16	
10- 10- 10- 10- 10- 10- 10- 10- 10- 10-	*	Hospitalization after base line	2594 (76.6)		1374 (80.1)	< 0.001	
§ 5-		·Percentag None of the presume					
		tThe P val noted above were confi	rmed in t	his study.	The impli-	terim mon-	
0 1 2 3 4 5 Years		toring analys tone patie cation is that rate contr	ol should	be consid	lered a pri-	torsade de	
No. or DEATHS number (percent)		pointes 72 hc mary approach to thera	py and th	at rhythm	control, if	torsade de	
Rhythm control 0 80 (4) 175 (9) 257 (13) 314 (18) 352 (24)		§Informatik used may be abandone				the rhythm-	
Rate control 0 78 (4) 148 (7) 210 (11) 275 (16) 306 (21)		group and 13 tory. Our data also sug				rate-control	
Figure 1. Cumulative Mortality from Any Cause in the Rhythm-Control Group and the Rate- Control Group.							
Time zero is the day of randomization. Data have been truncated at five years.		agulation is warranted i					
		lation and risk factors					
		rhythm appears to be a	restored a	and maint	ained.	🔍	
Minneapolis GRAND						10	
Foundation ROUNDS		Wyse DG, et al. A comparison of rate fibrillation. N Engl J Med. 2002 Dec 5					


15




























































































Figure 3. Mayo	Atrial F	ibrillatio	on-Specific	Sympto	om Inventory (M	AFSI) Frequ	iency Scor	es				
Mayo AF Symptom Inventory (MAFSI) Worksheet							B Between-group MAFSI frequency score difference					
back over the <u>past month</u> . Pl	How Often? (mark.one)					Interval,	No. of Patients Ablation (n = 1108)	No. of Patients Drug Rx (n = 1096)	Adjusted Mean Difference	Favors Drug Therapy	Favors Catheter Ablation	
						mo Baseline	()	1061	-0.2 (-0.7 to 0.4)			
Deleter based	Never	Rarely	Sometimes	Often	Always	3	897	894	-1.6 (-2.2 to -1.0)			
Palpitations heart fluttering/racing						12	828	831	-1.7 (-2.3 to -1.2)			
Slow heart beat						24	759	724	-1.7 (-2.3 to -1.1)			
Lightheadedness/dizziness						36	571	559	-1.2 (-1.9 to -0.6)		_	
Fainting/blackout/loss of consciousness						48	424	419	-0.8 (-1.6 to -0.1)			
Chest pain, pressure or				-		60	279	295	-1.3 (-2.1 to -0.5)			
fullness WITHOUT palpitations						All	3758	3722	-1.4 (-1.9 to -0.9)	r		
Shortness of breath										1.0 0.0	0 -0.5 -1.5 -2.5 In Difference (95% CI)	
Unable to exercise												
Tired/lack of energy					•	CAB	ANA Ra	ndomiz	ed trial of 22	204 patien	ts with	
Weakness						symp	otomati	c AF				
Feeling warm/flushed			П	п	•	Cath	eter abl	ation (v	's med thera	ıpy) signifi	cantly improved	
						guali	ty of life	e at 1 ve	ear			







49

